Financial Projections - The company expects a total profit loss of between -167 million and -143 million yuan for the year 2025, with a net profit attributable to shareholders of the parent company also in the range of -167 million to -143 million yuan[3]. - The projected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -191 million and -162 million yuan[3]. - The anticipated operating revenue for 2025 is between 45 million and 50 million yuan, representing a year-on-year increase of 78.46% to 98.29%[3]. - The operating revenue, after excluding unrelated business income and income without commercial substance, is also expected to be between 45 million and 50 million yuan[3]. - In the same period last year, the total profit was -151.37 million yuan, and the net profit attributable to shareholders of the parent company was -151.37 million yuan[5]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was -166.75 million yuan last year[5]. - The company reported an operating revenue of 25.22 million yuan in the previous year[7]. Product Development - The rapid growth in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) which has been approved for sale[8]. - The production line for the related product is still in the capacity ramp-up phase, with capacity expected to be gradually released[8]. - The company continues to maintain high levels of investment in research and development[9].
禾元生物(688765) - 2025 Q4 - 年度业绩预告